New combo aims to wipe out hidden leukemia cells

This study tests whether adding a new drug called revumenib to the usual treatment (blinatumomab plus chemotherapy) can better clear leftover leukemia cells in people with a specific genetic type of B-cell acute lymphoblastic leukemia (ALL) or mixed-lineage leukemia. About 90 adults and children with KMT2A-translocation leukemia who still have tiny amounts of disease after initial therapy will be randomly assigned to receive either the standard treatment alone or with revumenib. The goal is to see if the combination is safe and more effective at achieving a deep remission.